Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial

Journal Article

Duke Authors

Cited Authors

  • Schoenfeld, JD; Giobbie-Hurder, A; Ranasinghe, S; Kao, KZ; Lako, A; Tsuji, J; Liu, Y; Brennick, RC; Gentzler, R; Lee, C; Hubbard, J; Abbruzzese, JL; Jabbour, SK; Uboha, N; Stephans, K; Johnson, JM; Park, H; Villaruz, LC; Sharon, E; Streicher, H; Ahmed, M; Lyon, H; Cibuskis, C; Lennon, N; Jhaveri, A; Yang, L; Altreuter, J; Gunasti, L; Weirather, JL; Mak, RH; Awad, MM; Rodig, SJ; Chen, HX; Wu, CJ; Monjazeb, AM; Hodi, FS